Annual Drug Patent Expirations for ACTOPLUS+MET+XR
Actoplus Met Xr is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug and one Paragraph IV challenge.
ACTOPLUS MET XR drug price trends.
Drug patent litigation for ACTOPLUS MET XR.
This drug has eigthy-six patent family members in twenty-four countries.
The generic ingredient in ACTOPLUS MET XR is metformin hydrochloride; pioglitazone hydrochloride. One supplier is listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
